

INVERNESS MEDICAL INNOVATIONS INC  
Form 8-K  
May 04, 2005

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

---

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

---

Date of Report (Date of earliest event reported): **May 4, 2005**

**INVERNESS MEDICAL INNOVATIONS, INC.**

(Exact name of registrant as specified in charter)

<b>Delaware</b>	<b>1-16789</b>	<b>04-3565120</b>
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

**51 Sawyer Road, Suite 200, Waltham, Massachusetts 02453**

(Address of Principal Executive Offices) (Zip Code)

**(781) 647-3900**

Edgar Filing: INVERNESS MEDICAL INNOVATIONS INC - Form 8-K

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  
  - o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  
  - o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  
  - o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 7.01. Regulation FD Disclosure.**

Inverness Medical Innovations, Inc. (the Company ) has today made available on its website through the link <http://www.invernessmedical.com/investorrelations.cfm> an investor presentation which includes 2005 guidance which includes the Company's recently announced results of operations for the first quarter of 2005 (but excludes the impact of the recent Quidel settlement). The presentation also includes 2004 pro forma results and 2005 pro forma guidance which includes actual results for Binax, Inc. and Ischemia Technologies, Inc. as if acquired on January 1, 2004. The guidance and pro formas are provided on a cash adjusted basis and are reconciled to GAAP.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

INVERNESS MEDICAL INNOVATIONS, INC.





Edgar Filing: INVERNESS MEDICAL INNOVATIONS INC - Form 8-K

Date: May 4, 2005

By: /s/ Christopher J. Lindop  
Christopher J. Lindop  
Chief Financial Officer